zanidatamab zovodotin
medsir,zymeworks
['lung', 'zw49', 'medsir']
promising preliminary data from 1st-in-human trial of zw49 (anti-her2 bispecific adc) monotherapy, show antitumor activity @ 2.5mg/kg q3w in heavily pretreated pts with her2+ cancers (corr 31%) with manageable toxicity (no interstitial lung disease). #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM